STOCK TITAN

Lucid Diagnostics (LUCD) DEF 14A Filings

LUCD NASDAQ

Here are the DEF 14A proxy statements from Lucid Diagnostics Inc. (LUCD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow LUCD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LUCD filings page.

Rhea-AI Summary

Lucid Diagnostics Inc. is asking stockholders to elect three Class B directors, approve a major increase in authorized common shares, and ratify CBIZ CPAs P.C. as auditor at its June 24, 2026 virtual annual meeting.

The Authorized Capital Proposal would raise authorized common stock from 300,000,000 to 400,000,000 shares. As of April 27, 2026, 195,253,423 common shares were outstanding and large additional blocks were reserved for options, preferred stock and convertible notes, so more authorized shares would support financings, equity awards and conversions but could dilute existing holders and be used in anti-takeover contexts. PAVmed, the parent company, plans to vote in favor of all proposals.